GENE ONLINE|News &
Opinion
Blog

Heart Disease
‘Heart Attack on a Chip’ Sheds Light on Personalized Drugs Trials
2022-12-14
Bristol Myers Squibb’ sNDA for Rare Heart Disease Treatment Accepted by the FDA
2022-10-21
Potential Novel Anti-thrombotic Treatment by Ionis Pharmaceuticals
2022-07-28
Cytokinetics Poised to Begin Phase 3 after its HCM Drug Registers Encouraging Data
2021-07-21
Verve Makes Successful Wall Street Debut on Back of its Promising Base Editor
2021-06-20
With $41.9 Million from Oversubscribed Financing Round, XyloCor Sets Sights on Gene Therapy for Heart Disease
2021-03-23
Tenaya Raises $106 Million Series C Round To Fight Heart Disease
2021-03-04
Verve Raises $94M in Series B, Aims to Disrupt Cardiology Market with ‘Once-and-Done’ Gene Editing Therapies
2021-01-21
Why is Bristol Myers Squibb Investing $13.1 Billion in MyoKardia?
2020-10-06
Encouraging Performance of Cardiovascular Drug Vindicates Novartis’ $9.7 Billion Buyout Deal
2020-09-06
Verve Therapeutic’s One Time Base Editing Treatment Cuts Down Cholesterol Levels in Blood
2020-06-30
Weekly in Asia |Nov
2019-11-12
LATEST
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
EVENT
Scroll to Top